Loading...
In several trials, researchers have compared once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) with daily GLP-1RAs or other glucose-lowering drugs, but no head-to-head comparisons of once-weekly GLP-1RAs have been reported. To assess the comparative efficacy of once-weekly GLP-1RAs, researchers conducted a network meta-analysis of 34 randomized, controlled, phase III trials (≥24 weeks of follow-up) of albiglutide (Tanzuem), dulaglutide (Trulicity), and exenatide (Bydureon) in >21,000 adults with type 2 diabetes; analysis also covered taspoglutide, which is no longer being developed. Network meta-analysis is a statistical method for comparing interventions that have been examined in clinical trials but have not been compared d…